Industry Outlook

The Arterial Thrombectomy Devices market accounted for USD 478.5 Million in 2024 and is expected to reach USD 1,105.2 Million by 2035, growing at a CAGR of around 7.9% between 2025 and 2035. Arterial thrombectomy devices are specialized medical devices for removing blood clots from arteries.  These devices are crucial in treating acute ischemic stroke, peripheral artery disease, and other conditions where the clot blocks blood flow. The devices retrieve or dissolve the thrombus mechanically and restore normal blood flow. There is a growing market for these devices attributed to increased awareness of stroke care and increased cardiovascular disease awareness, progress in technologies, and increased demand for minimally invasive procedures.

Report Scope:

Market Dynamics

• The rising incidence of cardiovascular diseases (CVDs) such as stroke and peripheral artery disease

The increased occurrence of cardiovascular diseases (CVDs) is a major factor in the growing demand for arterial thrombectomy devices. Stroke is one of the main types of CVDs, affecting approximately 800,000 Americans each year, and about 140,000 cases result in death each year. CVD is listed as the world's leading cause of death according to the World Health Organization with nearly 17.9 million deaths, which is about 32% of the total deaths across the globe. In the U.S., the American Heart Association estimates coronary artery disease (CAD) affects roughly 18.1 million adult Americans and peripheral artery disease (PAD) affects approximately 9 million adults in the U.S. Growing need for effective treatment options is propelling the expansion of arterial thrombectomy devices market, as both patients and healthcare systems seek innovative solutions to combat the adverse effects of CVDs.

• Potential risks and complications, like vessel damage or embolization, may deter patients and healthcare providers

Arterial thrombectomy devices are essential for management of acute arterial occlusions, but there are inherent risks and complications associated with their use. A common concern is vessel injury, which can occur if the device tears or perforates the arterial wall. Vessel injury can result in severe hemorrhage or require further open intervention for vessel repair.  Another risk is embolization, in which parts of the thrombus/plaque are dislodged and embolized downstream to more distal. Overall, the risks of thrombectomy devices necessitate careful patient selection, detailed preoperative planning, and meticulous execution of the thrombectomy procedure to mitigate adverse events and ensure the benefits of the procedure outweigh the risks.

• Integration of thrombectomy devices with real-time imaging technologies, such as intraoperative ultrasound or fluoroscopy

The integration of thrombectomy devices with real-time imaging modalities, such as intraoperative ultrasound and intraoperative fluoroscopy, constitutes a remarkable innovation in interventional approaches. By utilizing these adjunct imaging modalities, the operator can achieve greater precision and efficacy in thrombus removal. Intraoperative ultrasound provides high-definition, real-time images and allows the operator to visualize the arteries and thrombus, guiding them during the procedure.

Meanwhile, fluoroscopy is a form of real-time imaging that provides continuous imaging of the catheter position and manipulation within the vascular system, which guides the deployment and retrieval of the thrombectomy device. The combination of intraoperative imaging modalities improves procedural success while also limiting the rate of complications, minimizing total procedure times, and improving overall patient safety. The combination of these modalities creates a more directed and efficient approach to managing thrombotic events. The development of integrations like these has opened new market opportunities by driving innovation in the medical device industry and expanding the range of solutions available for complex procedures.

Industry Experts Opinion

"The thrombectomy market is witnessing robust growth and the approval of the ICE system comes at an auspicious time. It is cutting-edge technology in an underpenetrated market"

• Shlomi Nachman, former Johnson & Johnson Company Group Chairman of Cardiovascular & Specialty Solutions and Vision.

“With hospitals increasingly short on staff and beds, physicians need a simple and effective tool that lets them restore arterial flow right on the table without resorting to time-consuming and costly adjunctive treatments”

• Gary Maharaj, President and CEO of Surmodics

Segment Analysis

Mechanical Thrombectomy Devices occupy a central position in the marketplace. These devices/technologies, including stent retriever devices and aspiration techniques, are very effective and demonstrate efficacy and applicability in the clinical setting.  And thus, widely utilized to remove blood clots from arteries. As a result of their performance in clinical trials and acceptance for use in hospital medicine, mechanical thrombectomy devices/technologies have become the accepted standard of care for the treatment of acute ischemic stroke and other arterial occlusions. While other segments, including ultrasound-assisted and laser-assisted thrombectomy devices and technologies, remain viable and useful options, they tend to be used in more specific applications.

From an application point of view Peripheral Arterial Disease, or PAD, stands out as a segment. PAD occurs when the peripheral arteries become narrow and often necessitates the establishment of blood flow using thrombectomy devices to minimize severe complications. The PAD segment is notable due to the prevalence of PAD in older adults and those with risk factors for PAD like diabetes and high blood pressure. The demand for advanced thrombectomy tools for PAD procedures is supported by their effectiveness in removing clots and reducing the risk of limb ischemia.

Regional Analysis

North America arterial thrombectomy devices market has witnessed advancements in medical technology along with the rising prevalence of arterial diseases. In United States, various healthcare infrastructure systems created an advantage in terms of innovative device adoption. According to AHA report of 2023, over 20 million Americans are affected with peripheral arterial disease and there is growing demand for thrombectomy solutions. The Canadian market is expanding as well, along with regional health policies devoted to improving vascular care. The Canadian Cardiovascular Society has found a steady increase in the amount of arterial thrombectomy procedures performed in Canada, indicative of future market potential. Government funding and health policies are accelerating the development and accessibility of vital arterial thrombectomy devices.

Competitive Landscape

The arterial thrombectomy devices market is highly competitive, driven by several key players known for their technological advancements and clinical innovations. Medtronic stands out with its comprehensive portfolio, including the Solitaire and Penumbra systems, which are widely recognized for their efficacy in treating stroke. Boston Scientific excels with its EMBOLD Thrombectomy Platform, offering a blend of precision and user-friendly design. Cerenovus, a Johnson & Johnson subsidiary, is renowned for its mechanical thrombectomy solutions like the CONTACT Aspiration System. Penumbra Inc. is a leader in aspiration-based thrombectomy, particularly with its Penumbra system. Stryker offers a diverse range of thrombectomy devices, emphasizing technological advancements and improved clinical outcomes. These companies are pivotal in driving the market forward with their innovative approaches and cutting-edge technologies.

Arterial Thrombectomy Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In April 2024, ICE Aspiration System received 510(k) clearance from the U.S. Food and Drug Administration. This development lands a new entrant in the thrombectomy market.
• In June 2023, Inari Medical launched two exciting new catheters for thrombectomy procedures. Among them, the Triever16 Curve catheter stands out for its versatility, making it suitable for treating both peripheral blood clots and pulmonary embolisms.

Report Coverage:

By Device Type

• Aspiration Thrombectomy Devices
• Mechanical Thrombectomy Devices
• Rheolytic Thrombectomy Devices
• Ultrasound-Assisted Thrombectomy Devices
• Laser-Based Thrombectomy Devices
• Others

By Application

• Peripheral Arterial Disease (PAD)
• Coronary Artery Disease (CAD)
• Ischemic Stroke
• Renal Artery Thrombosis
• Acute limb Ischemia
• Others

By End-user

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Academic and Research Institutions

Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Weigao Group (Argon Medical)
• Lemaitre Vascular Inc.
• Boston Scientific Corporation
• Medtronic Plc.
• Penumbra, Inc.
• Edwards Lifesciences Corporation
• Teleflex Incorporated
• Stryker Corporation
• Johnson & Johnson Services Inc.
• Terumo Corporation
• AngioDynamics
• Avinger, Inc.
• iVascular
• Xeltis

Frequently Asked Questions (FAQs)